Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder

10. november 2020 opdateret af: Jennifer Sweet, MD, University Hospitals Cleveland Medical Center
The overall goal of this study is to employ diffusion-weighted imaging (DWI) and tractography to investigate differences in connectivity in the rostral dorsal cingulum bundle (CB) in patients with bipolar disorder type I (BDI) or bipolar type II (BDII) compared to matched controls, and to utilize this information to determine if high-frequency deep brain stimulation (DBS) of the rostral dorsal CB has realistic potential as a therapy for producing mood stabilization in patients with BDI or BDII.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

45

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • University Hospitals Cleveland Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants from all three groups will be made up of those who respond to IRB approved advertisements or are referred by a provider within the UHCMC Department of Psychiatry or other provider referral.

Beskrivelse

  1. Inclusion and Exclusion Criteria for Group 1: Healthy Volunteers

    a. Inclusion Criteria for Group 1:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Physically healthy

    v. Without any current and/or lifetime psychiatric disorder assessed with a Structured Clinical Interview for psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI)

    b. Exclusion Criteria for Group 1:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Any psychiatric disorder including any severe personality disorder

    v. Currently pregnant or planning to become pregnant

    vi. Any other contraindications to the brain imaging procedures.

    vii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    viii. Currently taking any steroids, stimulants, or opioid pain killers.

    ix. Currently experiencing nicotine dependence or any smoking of cigarettes or use of other nicotine containing products within a week before the imaging visit.

  2. Inclusion and Exclusion Criteria for Group 2: Medically Treatment-Responsive Bipolar Disorder

    a. Inclusion Criteria for Group 2:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Meets diagnostic criteria for BDI or BDII according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the MINI

    v. A recent episode of depression, currently in remission with evidence-based treatments for bipolar disorder

    vi. Montgomery-Asberg Depression Rating Scale (MADRS) total score ≤ 10

    vii. Young Mania Rating Scale (YMRS, Young et al 1988) total score ≤ 8

    viii. Global Clinical Impression-Severity for Bipolar Disorder (CGI-S-BD) ≤ 2

    ix. Subject is compliant with taking medication per the investigator's discretion

    b. Exclusion Criteria for Group 2:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Contribution of any co-occurring psychiatric comorbidity that is disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD)

    v. Meets criteria for antisocial personality disorder

    vi. Meets criteria for having borderline personality disorder

    vii. There will be no exclusions based on prescribed CNS-active medications

    viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine

    x. Currently pregnant or planning to become pregnant

    xi. Any other contraindications to the brain imaging procedures.

  3. Inclusion and Exclusion Criteria for Group 3: Treatment-Refractory Bipolar Disorder

    a. Inclusion Criteria for Group 3:

    i. Male or female, age 18 or older

    ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements

    iii. In the opinion of the investigator, has the competency to understand and sign the informed consent

    iv. Meets diagnostic criteria for BDI or BDII, currently depressed, at least moderately severe with or without psychotic features, according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the Structured Clinical Interview for Psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI)

    v. Current episode lasting at least 6 months and not responding to 2 adequate evidence-based treatments for BDI or BDII assessed with the assistance of Modified Antidepressant Treatment History Form (MATHF) and verified through medical records if possible

    vi. If a subject has refused treatment with a particular FDA-approved mood stabilizer due to reasons of unacceptable side effects (such as weight gain, etc.), their wishes will be respected

    vii. Depression severity should be measured with Montgomery-Asberg Depression Rating Scale (MADRS). A MADRS total score ≥ 20 is required at Screening Visit/Baseline Evaluation.

    viii. Has experienced marked impairment as documented by a score consistent with severe impairment (7 or more on at least one of the three subscales of the Sheehan Disability Scale (SDS), which includes an assessment of work-life, family-life, and social life (no/mild impairment 0-3, moderate impairment 4-6, severe impairment 7-10)

    ix. Bipolar disorder and current depressive episode as the primary source of the patient's disability, according to both the subject and the psychiatrist

    b. Exclusion Criteria for Group 3:

    i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)

    ii. Progressive neurological disease such as neurodegenerative disease

    iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator)

    iv. Contribution of any co-occurring psychiatric comorbidity that disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD)

    v. Meets criteria for antisocial personality disorder

    vi. Meets criteria for having borderline personality disorder

    vii. There will be no exclusions based on prescribed CNS-active medications

    viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription

    ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine

    x. Active suicidal ideation with a plan or intent, a suicide attempt within past 6 months or more than 2 suicide attempts within the past 2 years

    xi. Currently pregnant or planning to become pregnant

    xii. Any other contraindications to the brain imaging procedures.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Healthy Volunteers
These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
Medically Treatment-Responsive BD
This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
Treatment-Refractory BD
This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Differences in connectivity in the rostral dorsal CB in patients with BDI or or BDII compared to matched controls
Tidsramme: Day 1
The imaging visit will consist of an MRI with diffusion-weighted imaging (DWI) sequences
Day 1

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Jennifer A Sweet, MD, University Hospitals Cleveland Medical Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. januar 2016

Primær færdiggørelse (Faktiske)

1. oktober 2019

Studieafslutning (Faktiske)

1. oktober 2019

Datoer for studieregistrering

Først indsendt

6. januar 2016

Først indsendt, der opfyldte QC-kriterier

12. januar 2016

Først opslået (Skøn)

14. januar 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2020

Sidst verificeret

1. november 2020

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 02-15-35
  • KL2TR000440 (U.S. NIH-bevilling/kontrakt)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Maniodepressiv

Kliniske forsøg med MR scanning

3
Abonner